Addition of Docetaxel to First-line Long-term Hormone Therapy in Prostate Cancer (STAMPEDE): Modelling to Estimate Long-term Survival, Quality-adjusted Survival, and Cost-effectiveness

Woods, Beth S; Sideris, Eleftherios; Sydes, Matthew R; Gannon, Melissa R; Parmar, Mahesh KB; Alzouebi, Mymoona; Attard, Gerhardt; Birtle, Alison J; Brock, Susannah; Cathomas, Richard; +34 more... Chakraborti, Prabir R; Cook, Audrey; Cross, William R; Dearnaley, David P; Gale, Joanna; Gibbs, Stephanie; Graham, John D; Hughes, Robert; Jones, Rob J; Laing, Robert; Mason, Malcolm D; Matheson, David; McLaren, Duncan B; Millman, Robin; O'Sullivan, Joe M; Parikh, Omi; Parker, Christopher C; Peedell, Clive; Protheroe, Andrew; Ritchie, Alastair WS; Robinson, Angus; Russell, J Martin; Simms, Matthew S; Srihari, Narayanan N; Srinivasan, Rajaguru; Staffurth, John N; Sundar, Santhanam; Thalmann, George N; Tolan, Shaun; Tran, Anna TH; Tsang, David; Wagstaff, John; James, Nicholas D; Sculpher, Mark J; (2018) Addition of Docetaxel to First-line Long-term Hormone Therapy in Prostate Cancer (STAMPEDE): Modelling to Estimate Long-term Survival, Quality-adjusted Survival, and Cost-effectiveness. EUROPEAN UROLOGY ONCOLOGY, 1 (6). pp. 449-458. ISSN 2588-9311 DOI: https://doi.org/10.1016/j.euo.2018.06.004

Permanent Identifier

Use this Digital Object Identifier when citing or linking to this resource.

https://doi.org/10.1016/j.euo.2018.06.004

Abstract

Share

Download

Filename: STAMPEDE DOC CEA.pdf

Licence: Creative Commons: Attribution 3.0

Download
[img]

Downloads

View details

Metrics & Citations


Google Scholar